{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:23:30Z","timestamp":1761675810128,"version":"build-2065373602"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jim.2025.113969","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:14:19Z","timestamp":1756397659000},"page":"113969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunogenicity, biodistribution, and toxicology evaluation of Mycobacterium tuberculosis ag85a plasmid DNA in cynomolgus monkeys, mice and guinea pigs"],"prefix":"10.1016","volume":"544","author":[{"given":"Danyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yourong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"08","key":"10.1016\/j.jim.2025.113969_bb0005","first-page":"797","article-title":"Preliminary evaluation of the general toxicity of BCG-CpG-DNA","volume":"23","author":"Aihua","year":"2010","journal-title":"Chin. J. Biol. Prod."},{"key":"10.1016\/j.jim.2025.113969_bb0010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/1471-2334-14-487","article-title":"Protective efficacy of toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice","volume":"14","author":"Chen","year":"2014","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.jim.2025.113969_bb0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/14712598.2017.1265940","article-title":"Present and future DNA vaccines for chronic hepatitis B treatment","volume":"17","author":"Cova","year":"2017","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.jim.2025.113969_bb0020","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00204-021-03221-x","article-title":"Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque","volume":"96","author":"Dai","year":"2022","journal-title":"Arch. Toxicol."},{"issue":"2","key":"10.1016\/j.jim.2025.113969_bb0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21010\/ajid.v13i2.2","article-title":"Expression of immunoglobulin, granzyme-B AND perforin against Ag85A AND Ag85B proteins of Mycobacterium tuberculosis in BALB\/C mice","volume":"13","author":"Fihiruddin","year":"2019","journal-title":"Afr J Infect Dis."},{"issue":"7","key":"10.1016\/j.jim.2025.113969_bb0030","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02260-20","article-title":"COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice","volume":"95","author":"Garcia-Arriaza","year":"2021","journal-title":"J. Virol."},{"issue":"10120","key":"10.1016\/j.jim.2025.113969_bb0035","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jim.2025.113969_bb0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fimmu.2014.00256","article-title":"Innovative strategies to identify M. Tuberculosis antigens and epitopes using genome-wide analyses","volume":"5","author":"Geluk","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2025.113969_bb0045","first-page":"504","article-title":"Distribution and long-term toxicity of therapeutic HBV DNA vaccine in mouse tissues","volume":"06","author":"Guoyu","year":"2003","journal-title":"Chin. PLA Med. J."},{"issue":"8","key":"10.1016\/j.jim.2025.113969_bb0050","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm0896-893","article-title":"Immunogenicity and protective efficacy of a tuberculosis DNA vaccine","volume":"2","author":"Huygen","year":"1996","journal-title":"Nat. Med."},{"issue":"10332","key":"10.1016\/j.jim.2025.113969_bb0055","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jim.2025.113969_bb0060","article-title":"Plant-produced N-glycosylated Ag85A exhibits enhanced vaccine efficacy against Mycobacterium tuberculosis HN878 through balanced multifunctional Th1 T cell immunity","volume":"8","author":"Kim","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.jim.2025.113969_bb0065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41541-021-00419-z","article-title":"Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2","volume":"6","author":"Lassauniere","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"4\u20136","key":"10.1016\/j.jim.2025.113969_bb0070","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000053993","article-title":"Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice","volume":"43","author":"Ledwith","year":"2000","journal-title":"Intervirology"},{"key":"10.1016\/j.jim.2025.113969_bb0075","first-page":"33","article-title":"Plasmid DNA vaccines: assay for integration into host genomic DNA","volume":"104","author":"Ledwith","year":"2000","journal-title":"Dev. Biol. (Basel)"},{"issue":"1","key":"10.1016\/j.jim.2025.113969_bb0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2014.12.036","article-title":"CD226 as a genetic adjuvant to enhance immune efficacy induced by Ag85A DNA vaccination","volume":"25","author":"Li","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"35","key":"10.1016\/j.jim.2025.113969_bb0085","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1016\/j.vaccine.2008.06.066","article-title":"The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin","volume":"26","author":"Liang","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jim.2025.113969_bb0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-3083.2011.02538.x","article-title":"Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs","volume":"74","author":"Liang","year":"2011","journal-title":"Scand. J. Immunol."},{"issue":"3","key":"10.1016\/j.jim.2025.113969_bb0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/1574-695X.12008","article-title":"Immunogenicity and therapeutic effects of Ag85A\/B chimeric DNA vaccine in mice infected with Mycobacterium tuberculosis","volume":"66","author":"Liang","year":"2012","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.jim.2025.113969_bb0100","article-title":"Immunotherapeutic effects of different doses of Mycobacterium tuberculosis ag85a\/b DNA vaccine delivered by electroporation","volume":"13","author":"Liang","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jim.2025.113969_bb0105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jim.2025.113969_bb0110","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/395626","article-title":"A Mycobacterium bovis BCG-naked DNA prime-boost vaccination strategy induced CD4(+) and CD8(+) T-cell response against Mycobacterium tuberculosis immunogens","volume":"2014","author":"Lu","year":"2014","journal-title":"J Immunol Res"},{"issue":"4\u20136","key":"10.1016\/j.jim.2025.113969_bb0115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000053994","article-title":"Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA","volume":"43","author":"Manam","year":"2000","journal-title":"Intervirology"},{"issue":"4","key":"10.1016\/j.jim.2025.113969_bb0120","first-page":"289","article-title":"Immunogenicity of a DNA vaccine encoding Ag85a-Tb10.4 antigens from Mycobacterium tuberculosis","volume":"13","author":"Meshkat","year":"2016","journal-title":"Iran. J. Immunol."},{"issue":"38","key":"10.1016\/j.jim.2025.113969_bb0125","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1016\/j.vaccine.2016.07.055","article-title":"Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4(+) T cells but no increase in avidity for Ag85A","volume":"34","author":"Metcalfe","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2025.113969_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.581812","article-title":"IL-12 DNA displays efficient adjuvant effects improving immunogenicity of Ag85A in DNA prime\/MVA boost immunizations","volume":"10","author":"Morelli","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"301","key":"10.1016\/j.jim.2025.113969_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7462","article-title":"A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates","volume":"7","author":"Muthumani","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.jim.2025.113969_bb0140","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3109\/21691401.2014.966195","article-title":"Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes","volume":"44","author":"Pabreja","year":"2016","journal-title":"Artif Cells Nanomed Biotechnol."},{"issue":"5","key":"10.1016\/j.jim.2025.113969_bb0145","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/10430349950018508","article-title":"Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits","volume":"10","author":"Parker","year":"1999","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.jim.2025.113969_bb0150","article-title":"Ag85A DNA vaccine delivery by nanoparticles: influence of the formulation characteristics on immune responses","volume":"4","author":"Poecheim","year":"2016","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.jim.2025.113969_bb0155","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1128\/IAI.00786-13","article-title":"Mucosal vaccination against tuberculosis using inert bioparticles","volume":"81","author":"Reljic","year":"2013","journal-title":"Infect. Immun."},{"issue":"8","key":"10.1016\/j.jim.2025.113969_bb0160","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/gt.2015.35","article-title":"Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine","volume":"22","author":"Riede","year":"2015","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.jim.2025.113969_bb0165","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00649-19","article-title":"Unraveling the role of MicroRNAs in Mycobacterium tuberculosis infection and disease: advances and pitfalls","volume":"88","author":"Ruiz-Tagle","year":"2020","journal-title":"Infect. Immun."},{"issue":"38","key":"10.1016\/j.jim.2025.113969_bb0170","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1016\/j.vaccine.2023.07.067","article-title":"Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates","volume":"41","author":"Shears","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2025.113969_bb0175","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mehy.2015.11.015","article-title":"BCG vaccine fails to prevent the reactivation of latent tuberculosis","volume":"88","author":"Syal","year":"2016","journal-title":"Med. Hypotheses"},{"issue":"13\u201314","key":"10.1016\/j.jim.2025.113969_bb0180","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.vaccine.2003.09.052","article-title":"Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery","volume":"22","author":"Thomsen","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2025.113969_bb0185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijid.2021.06.045","article-title":"Prevalence of latent TB and effectiveness of BCG vaccination against latent tuberculosis: an observational study","volume":"109","author":"Trollfors","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.jim.2025.113969_bb0190","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.vaccine.2004.08.004","article-title":"Biodistribution and general safety of a naked DNA plasmid, GTU-MultiHIV, in a rat, using a quantitative PCR method","volume":"23","author":"Tuomela","year":"2005","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.jim.2025.113969_bb0195","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2005.16.1143","article-title":"I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution\/persistence and integration","volume":"16","author":"Vilalta","year":"2005","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.jim.2025.113969_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.854","article-title":"Mechanisms of ag85a\/b DNA vaccine conferred immunotherapy and recovery from Mycobacterium tuberculosis-induced injury","volume":"11","author":"Wang","year":"2023","journal-title":"Immun Inflamm Dis."},{"issue":"16","key":"10.1016\/j.jim.2025.113969_bb0205","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/j.vaccine.2023.03.015","article-title":"Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial","volume":"41","author":"Wilson","year":"2023","journal-title":"Vaccine"},{"year":"2024","series-title":"Global tuberculosis report 2024","author":"World Health O","key":"10.1016\/j.jim.2025.113969_bb0210"},{"key":"10.1016\/j.jim.2025.113969_bb0215","article-title":"Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Microbiol."},{"issue":"251","key":"10.1016\/j.jim.2025.113969_bb0220","article-title":"An immune-enhanced multivalent DNA nanovaccine to prevent H7 and H9 avian influenza virus in mice","volume":"12","author":"Xu","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.jim.2025.113969_bb0225","first-page":"804","article-title":"Expression and immunogenicity of Ag85A protein of Mycobacterium tuberculosis","volume":"56","author":"Xu","year":"2016","journal-title":"Wei Sheng Wu Xue Bao"},{"issue":"2","key":"10.1016\/j.jim.2025.113969_bb0230","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7774\/cevr.2014.3.2.155","article-title":"Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis","volume":"3","author":"Yuk","year":"2014","journal-title":"Clin Exp Vaccine Res."},{"key":"10.1016\/j.jim.2025.113969_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104487","article-title":"Integrated transcriptomic and quantitative proteomic analysis identifies potential RNA sensors that respond to the Ag85A DNA vaccine","volume":"149","author":"Zhai","year":"2020","journal-title":"Microb. Pathog."},{"issue":"1","key":"10.1016\/j.jim.2025.113969_bb0240","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12951-019-0528-5","article-title":"Dynamic profiles, biodistribution and integration evaluation after intramuscular\/intravenous delivery of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in vaccinated normal rodent","volume":"17","author":"Zhao","year":"2019","journal-title":"J Nanobiotechnol."},{"key":"10.1016\/j.jim.2025.113969_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127907","article-title":"Immunogenicity without Efficacy of an Adenoviral Tuberculosis Vaccine in a Stringent Mouse Model for Immunotherapy during Treatment","volume":"10","author":"Alyahya","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jim.2025.113969_bb0250","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/a-1785-3936","article-title":"A new intranasal influenza vector-based vaccine TB\/FLU-04L against tuberculosis: Preclinical safety studies","volume":"72","author":"Buzitskaya","year":"2022","journal-title":"Drug Res (Stuttg)"},{"key":"10.1016\/j.jim.2025.113969_bb0255","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.vaccine.2015.02.004","article-title":"The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells\/mm(3)","volume":"33","author":"Churchyard","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2025.113969_bb0260","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.4049\/jimmunol.1400676","article-title":"Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge","volume":"193","author":"Darrah","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jim.2025.113969_bb0265","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.vetimm.2014.01.010","article-title":"Effect of dose and route of immunisation on the immune response induced in cattle by heterologous Bacille Calmette-Guerin priming and recombinant adenoviral vector boosting","volume":"158","author":"Dean","year":"2014","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.jim.2025.113969_bb0270","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1016\/j.vaccine.2014.09.001","article-title":"The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses","volume":"32","author":"Kagina","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2025.113969_bb0275","article-title":"MVA85A vaccine to enhance BCG for preventing tuberculosis","volume":"4","author":"Kashangura","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jim.2025.113969_bb0280","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/ije\/dyv142","article-title":"Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review","volume":"44","author":"Kashangura","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jim.2025.113969_bb0285","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.vaccine.2016.01.062","article-title":"A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults","volume":"34","author":"Minhinnick","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2025.113969_bb0290","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.vaccine.2021.01.034","article-title":"Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model","volume":"39","author":"Pinpathomrat","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2025.113969_bb0295","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4161\/hv.22464","article-title":"Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial","volume":"9","author":"Rowland","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jim.2025.113969_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141687","article-title":"A phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults","volume":"10","author":"Sheehan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jim.2025.113969_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087439","article-title":"Preclinical evaluation of TB\/FLU-04L-An intranasal influenza vector-based boost vaccine against tuberculosis","volume":"24","author":"Shurygina","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jim.2025.113969_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.673532","article-title":"A 2-dose AERAS-402 regimen boosts CD8(+) polyfunctionality in HIV-negative, BCG-vaccinated recipients","volume":"12","author":"Sivakumaran","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jim.2025.113969_bb0315","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1586\/14760584.2014.929947","article-title":"Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future?","volume":"13","author":"Smaill","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jim.2025.113969_bb0320","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/a-1771-5985","article-title":"Preclinical safety evaluation: Acute and repeated-dose toxicity of a new intranasal recombinant vector vaccine TB\/FLU-04L against tuberculosis","volume":"72","author":"Stosman","year":"2022","journal-title":"Drug Res (Stuttg)"},{"key":"10.1016\/j.jim.2025.113969_bb0325","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2025.113969_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087340","article-title":"The candidate TB vaccine, MVA85A, induces highly durable Th1 responses","volume":"9","author":"Tameris","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jim.2025.113969_bb0335","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1016\/j.vaccine.2015.03.070","article-title":"'A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants","volume":"33","author":"Tameris","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2025.113969_bb0340","first-page":"8","article-title":"'Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study","author":"Tkachuk","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jim.2025.113969_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176784","article-title":"Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models","volume":"12","author":"Tkachuk","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jim.2025.113969_bb0350","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3389\/fimmu.2020.01806","article-title":"The systematic review and meta-analysis on the immunogenicity and safety of the tuberculosis subunit vaccines M72\/AS01(E) and MVA85A","volume":"11","author":"Ullah","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jim.2025.113969_bb0355","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201603-0654OC","article-title":"Safety and immunogenicity of adenovirus 35 tuberculosis vaccine candidate in adults with active or previous tuberculosis A randomized trial","volume":"195","author":"van Zyl-Smit","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jim.2025.113969_bb0360","article-title":"First-in-human trials of GamTBvac, a recombinant subunit tuberculosis vaccine candidate: Safety and immunogenicity assessment","volume":"7","author":"Vasina","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jim.2025.113969_bb0365","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2567.2004.01903.x","article-title":"Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin","volume":"112","author":"Vordermeier","year":"2004","journal-title":"Immunology"},{"key":"10.1016\/j.jim.2025.113969_bb0370","article-title":"Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial","author":"Wajja","year":"2023","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175925001693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175925001693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:00:24Z","timestamp":1761674424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175925001693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":74,"alternative-id":["S0022175925001693"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2025.113969","relation":{},"ISSN":["0022-1759"],"issn-type":[{"type":"print","value":"0022-1759"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity, biodistribution, and toxicology evaluation of Mycobacterium tuberculosis ag85a plasmid DNA in cynomolgus monkeys, mice and guinea pigs","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2025.113969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113969"}}